This fully human is capable of specifically binding to PD-L1. The anti-PD-L1 antibody was screened by the yeast display technology. This antibody specifically binds to PD-L1 with an EC₅₀ value of 0.2 μg/ml in an ELISA assay. In the competitive ELISA assay detecting the blocking ability of this antibody, it got an IC₅₀ value of 1.14 μg/ml. This antibody also has an inhibitory activity to tumor growth in animal models. It can be potentially used for the detection and immunotherapy studies of tumors associated with the use of PD-L1.
Figure 1 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.
Binding activity of mAb B60-55 to hPD-L1 protein by ELISA.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 2 Figure 2 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.
The binding of mAb B60-55 to hPD-L1 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 3 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.
The binding of mAb B60-55 to hB7H3 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 4 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.
The binding of mAb B60-55 to hPD-L2 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 5 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.
The binding of mAb B60-55 to mPD-L1 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 6 Specific binding of mAb B60-55 for human or cynomolgus PD-L1.
The binding of mAb B60-55 to cPD-L1 protein expressing in HEK293 cells compared with HEK293 cell not express certain proteins; The data shown as statistical analysis of the mean fluorescence intensity in various group.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 7 B60-55 mAb competitively bind to PD-L1 with PD1. Competitive ELISA.
Binding activity of mAb B60-55 to PD-L1 previously immobilized on ELISA plates in the presence of certain amount of PD1.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 8 B60-55 mAb competitively bind to PD-L1 with CD80. Competitive ELISA.
Binding activity of mAb B60-55 to PD-L1 previously immobilized on ELISA plates in the presence of certain amount of CD80.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 9 B60-55 mAb overcomes PD-L1-mediated inhibition of T-cell activation.
Activation effects of anti-PD-L1 mAbs on PBMCs. Isolated PBMCs were added to 96-well flat-bottomed tissue culture plates at 2 × 105 cells/well activated by anti-CD3 (1 μg/ml) and anti-CD28 (0.2 μg/ml) in the presence of 2 μg/ml mAb B60-55 or isotype control antibody. Plates were cultured at 37 °C in a humidified incubator with 5% CO2 for five days. The levels of IFN-γ were measured by ELISA assay.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 10 B60-55 mAb overcomes PD-L1-mediated inhibition of T-cell activation.
Anti-PD-L1 mAb B60-55 enhanced the activation of CD4+ T cells in a dendritic cell-T cell mixed lymphocyte assay. The EC50 of mAb B60-55 for IFN-γ levels on dendritic cell-T cell mixed lymphocyte assay was 0.189 μg/ml.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 11 B60-55 mAb overcomes PD-L1-mediated inhibition of T-cell activation.
The expression of PDL1 and HLA-DR on dendritic cell-T cell were detected by flow cytometry.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 12 Therapeutic effect of anti-PD-L1 antibodies in mouse tumor models.
A375/PBMCs (5:1) mixed cells were inoculated s.c. into the right flank of female NOD/SCID mice. Treatment with anti-PD-L1 antibodies (BII 61-62, B60-55 and MEDI4736) or isotype control was initiated on day 0 at 3 mg/kg, and continued with another 3 doses once per week by i.p. injection.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
Figure 13 Preliminary PK study in cynomolgus monkey.
The B60-55 mAb serum concentration versus time profiles for 6 mg/kg doses in one male cynomolgus monkey.
Luan, Y., Chai, D., Peng, J., Ma, S., Wang, M., Ma, H., ... & Qin, S. (2016). A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. International immunopharmacology, 31, 248-256.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-305-sdAb | Recombinant Anti-Mouse Cd274 VHH Single Domain Antibody | IHC, IP, FC, Neut, FUNC | Llama VHH |
HPAB-N0408-YC-VHH | Recombinant Humanized Anti-CD274 Single Domain Antibody (PDL1-56dAb) | ELISA, FC, BL | Human VHH |
HPAB-N0307-YC-VHH | Recombinant Humanized Anti-CD274 Single Domain Antibody (NOV013YC) | ELISA, FC, BL | Humanized VHH |
NBD-0065-YJ-VHH | Camelid Anti-CD274 Recombinant Single Domain Antibody (CBP112D) | ELISA | Camelid VHH |
NBD-0066-YJ-VHH | Camelid Anti-CD274 Recombinant Single Domain Antibody (KN035) | ELISA, Inihb | Camelid VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0190CL | Anti-Human CD274 Recombinant Antibody (PD1-AB1) | FC, ELISA, FuncS | |
TAB-0190CL-F(E) | Anti-Human CD274 Recombinant Antibody Fab Fragment (PD1-AB1) | FC, ELISA, FuncS | |
TAB-1008CL-F(E) | Human Anti-CD274 Recombinant Antibody; Fab Fragment (TAB-1008CL-F(E)) | FC | Human Fab |
TAB-0998CL-S(P) | Anti-Human CD274 Recombinant Antibody scFv Fragment (BII61-62) | ELISA | Human antibody |
TAB-0999CL-S(P) | Anti-Human CD274 Recombinant Antibody scFv Fragment (B50-6) | ELISA | Human antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0262CL | Mouse Anti-CD274 Recombinant Antibody (TAB-0262CL) | ELISA, WB, SPR, ADCC, CDC, FuncS | Mouse IgG |
TAB-1009CL-S(P) | Mouse Anti-CD274 Recombinant Antibody; scFv Fragment (TAB-1009CL-S(P)) | WB, IHC | Mouse scFv |
TAB-1010CL-S(P) | Anti-Human CD274 Recombinant Antibody scFv Fragment | FC | |
TAB-1011CL-S(P) | Mouse Anti-CD274 Recombinant Antibody; scFv Fragment (TAB-1011CL-S(P)) | ELISA | Mouse scFv |
TAB-0262CL-F(E) | Mouse Anti-CD274 Recombinant Antibody; Fab Fragment (TAB-0262CL-F(E)) | ELISA, WB, SPR, FuncS | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0263CL | Human Anti-CD274 Recombinant Antibody (TAB-0263CL) | ELISA, WB, SPR, FuncS | Humanized IgG |
TAB-0264CL | Human Anti-CD274 Recombinant Antibody (TAB-0264CL) | ELISA, WB, SPR, ADCC, CDC, FuncS, Inhib | Humanized IgG |
TAB-0265CL | Human Anti-CD274 Recombinant Antibody (TAB-0265CL) | ELISA, WB, SPR, ADCC, CDC, FuncS | Humanized IgG |
TAB-0266CL | Human Anti-CD274 Recombinant Antibody (TAB-0266CL) | ELISA, WB, SPR, ADCC, CDC, FuncS | Humanized IgG |
TAB-0267CL | Human Anti-CD274 Recombinant Antibody (TAB-0267CL) | ELISA, WB, SPR, ADCC, CDC, FuncS | Humanized IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-0995CL | Human Anti-CD274 Recombinant Antibody (TAB-0995CL) | ELISA, FC | Chimeric (Mouse/Human) IgG1, κ |
TAB-0995CL-S(P) | Human Anti-CD274 Recombinant Antibody; scFv Fragment (TAB-0995CL-S(P)) | ELISA, FC | Human scFv |
TAB-0995CL-F(E) | Human Anti-CD274 Recombinant Antibody; Fab Fragment (TAB-0995CL-F(E)) | ELISA, FC | Chimeric (Mouse/Human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-324CQ | Mouse Anti-CD274 Recombinant Antibody (clone 29E.2A3.C6) | IHC-P, FC, Neut, ICC | Mouse IgG2b, κ |
NEUT-325CQ | Human Anti-CD274 Recombinant Antibody (clone CBLS-206) | Neut | Human IgG1, κ |
NEUT-326CQ | Human Anti-CD274 Recombinant Antibody (clone CBLS-207) | ELISA, Neut | Human IgG1, κ |
NEUT-327CQ | Mouse Anti-CD274 Recombinant Antibody (clone MIH1) | FC, FuncS, Neut, IHC, IF | Mouse IgG1, κ |
NEUT-330CQ | Rat Anti-CD274 Recombinant Antibody (clone MIH5) | FC, FuncS, Neut, IHC-Fr, WB | Rat IgG2a, λ |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-328CQ | Rat Anti-CD274 Recombinant Antibody (VMC171) | Block, FC | Rat IgG2 |
NEUT-329CQ | Rat Anti-CD274 Recombinant Antibody (clone 10F.9G2) | FC, IF, Block | Rat IgG2b, κ |
NEUT-331CQ | Mouse Anti-CD274 Recombinant Antibody (clone alphaPD-L1) | ELISA, Block | Mouse IgG1, λ |
NEUT-332CQ | Rabbit Anti-CD274 Recombinant Antibody (clone CBL1009) | Block | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-0548 | Hi-Affi™ Rabbit Anti-CD274 Recombinant Antibody (clone DS548AB) | ELISA | Rabbit IgG |
MOR-4049 | Hi-Affi™ Rabbit Anti-CD274 Recombinant Antibody (clone SI116DS) | ELISA | Rabbit IgG |
MOR-4050 | Hi-Affi™ Rabbit Anti-CD274 Recombinant Antibody (clone SI117DS) | ICC, IF, FC | Rabbit IgG |
MOR-4051 | Hi-Affi™ Rabbit Anti-CD274 Recombinant Antibody (clone SI118DS) | FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-N0407-YC | Human Anti-CD274 Recombinant Antibody; VHH-Fc Fragment (HPAB-N0407-YC) | FuncS, ELISA, Block | Human VHH-Fc |
MRO-1200-CN | Rabbit Anti-CD274 Recombinant Antibody (clone CBACN-439) | WB, IHC | Rabbit IgG |
MRO-1742-CN | Rabbit Anti-CD274 Polyclonal Antibody (MRO-1742-CN) | WB, IF, IHC, FC | Rabbit IgG |
MRO-1745-CN | Rabbit Anti-CD274 Polyclonal Antibody (MRO-1745-CN) | WB, IF | Rabbit IgG |
HPAB-0336-FY | Human Anti-CD274 Recombinant Antibody (clone Mi 185-6) | ELISA | Human IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0561LY-F(E) | Human Anti-CD274 Recombinant Antibody; Fab Fragment (HPAB-0561LY-F(E)) | ELISA, Block | Chimeric (mouse/human) Fab |
HPAB-0562LY-F(E) | Human Anti-CD274 Recombinant Antibody; Fab Fragment (HPAB-0562LY-F(E)) | ELISA, Block | Chimeric (mouse/human) Fab |
HPAB-0563LY-F(E) | Human Anti-CD274 Recombinant Antibody; Fab Fragment (HPAB-0563LY-F(E)) | ELISA, Block | Chimeric (mouse/human) Fab |
HPAB-0564LY-F(E) | Human Anti-CD274 Recombinant Antibody; Fab Fragment (HPAB-0564LY-F(E)) | ELISA, Block | Chimeric (mouse/human) Fab |
HPAB-0565LY-F(E) | Human Anti-CD274 Recombinant Antibody; Fab Fragment (HPAB-0565LY-F(E)) | ELISA, Block | Chimeric (mouse/human) Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-417CQ | Afuco™ Anti-CD274 ADCC Recombinant Antibody (Durvalumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
AFC-TAB-418CQ | Afuco™ Anti-CD274 ADCC Recombinant Antibody (Atezolizumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, BL | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-2514LY-S(P) | Human Anti-CD274 Recombinant Antibody; scFv Fragment (HPAB-2514LY-S(P)) | FC | Human scFv |
HPAB-2515LY-S(P) | Human Anti-CD274 Recombinant Antibody; scFv Fragment (HPAB-2515LY-S(P)) | ELISA, FC, Block | Human scFv |
HPAB-2516LY-S(P) | Human Anti-CD274 Recombinant Antibody; scFv Fragment (HPAB-2516LY-S(P)) | ELISA, FC, Block | Human scFv |
HPAB-N0033-YC-S(P) | Mouse Anti-CD274 Recombinant Antibody (clone 3A7); scFv Fragment | ELISA, FC, IHC | Mouse scFv |
HPAB-N0035-YC-S(P) | Human Anti-CD274 Recombinant Antibody; scFv Fragment (HPAB-N0035-YC-S(P)) | FC, Block | Human scFv |
There are currently no Customer reviews or questions for TAB-0997CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.